Paratek Pharmaceuticals, Inc. [PRTK]

Source: 

Company Overview

We area commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use. Our United States, or U.S., Food and Drug Administration, or FDA, approved commercial product, NUZYRA(omadacycline) is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, and acute skin and skin structure infections, or ABSSSI, caused by susceptible pathogens. SEYSARA(sarecycline) is an FDA-approved product with respect to which we have exclusively licensed in the U.S.